Alexandra Hospital

Athens, Attikí 11528

0 studies enrolling now · 8 studies all time

What they study most

Abiraterone Acetate, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Breast Cancer, Breast Neoplasm, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Diabetes, Enzyme Inhibitors

Studies at this site

• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer — Stopped early
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed